NEW YORK, NY / ACCESSWIRE / September 13, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

SRAC Shareholders Click Here: https://www.zlk.com/pslra-1/stable-road-acquisition-corp-information-request-form-2?prid=19527&wire=1
VIEW Shareholders Click Here: https://www.zlk.com/pslra-1/view-inc-f-k-a-cf-finance-acquisition-corp-ii-loss-submission-form?prid=19527&wire=1
SPPI Shareholders Click Here: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?prid=19527&wire=1

* ADDITIONAL INFORMATION BELOW *

Stable Road Acquisition Corp. (NASDAQ:SRAC)

SRAC Lawsuit on behalf of: investors who purchased October 7, 2020 - July 13, 2021
Lead Plaintiff Deadline : September 13, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/stable-road-acquisition-corp-information-request-form-2?prid=19527&wire=1

According to the filed complaint, during the class period, Stable Road Acquisition Corp. made materially false and/or misleading statements and/or failed to disclose that: (a) Stable Road's acquistion target, Momentus's 2019 test of its key technology, a water plasma thruster, had failed to meet Momentus's own public and internal pre-launch criteria for success, and was conducted on a prototype that was not designed to generate commercially significant amounts of thrust; (b) the U.S. government had conveyed that it considered Momentus's Chief Executive Officer a national security threat, jeopardizing his continued leadership of Momentus and Momentus's launch schedule and business prospects; (c) consequently, the revenue projections and business and operational plans provided to investors regarding Momentus and the commercial viability and timeline of its products were materially false and misleading and lacked a reasonable basis in fact; and (d) Stable Road had failed to conduct appropriate due diligence of Momentus and its business operations and defendants had materially misrepresented the due diligence activities being conducted by Stable Road executives and its sponsor in connection with the merger.

View, Inc. f/k/a CF Finance Acquisition Corp. II (NASDAQ:VIEW)

VIEW Lawsuit on behalf of: investors who purchased November 30, 2020 - August 16, 2021
Lead Plaintiff Deadline : October 18, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/view-inc-f-k-a-cf-finance-acquisition-corp-ii-loss-submission-form?prid=19527&wire=1

According to the filed complaint, during the class period, View, Inc. f/k/a CF Finance Acquisition Corp. II made materially false and/or misleading statements and/or failed to disclose that: (1) View had not properly accrued warranty costs related to its product; (2) there was a material weakness in View's internal controls over accounting and financial reporting related to warranty accrual; (3) as a result, the Company's financial results for prior periods were misstated; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)

SPPI Lawsuit on behalf of: investors who purchased December 27, 2018 - August 5, 2021
Lead Plaintiff Deadline : November 1, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?prid=19527&wire=1

According to the filed complaint, during the class period, Spectrum Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP